Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477451 · ClinicalTrials.gov registry record · Phase 2
Staccato Alprazolam in Panic Attack
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00477451 is a Phase 2 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 49 participants.
The verdict
NCT00477451, a Phase 2 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
We are developing Staccato™ Alprazolam for the treatment of Panic attacks associated with panic disorder. This study will provide an initial assessment of efficacy, and to continue to describe the tolerability and pharmacokinetics, of a single inhaled dose of Staccato Alprazolam on a doxapram-induced panic attack in patients with panic disorder.
Interventions
- DRUG Inhaled placebo
- DRUG Inhaled alprazolam 1 mg
- DRUG Inhaled alprazolam 2 mg
- DRUG IV doxapram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477451
The ClinicalTrials.gov registry entry for NCT00477451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Inhaled placebo is the first listed.
NCT00477451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477451 about?
NCT00477451 is a clinical study titled "Staccato Alprazolam in Panic Attack". We are developing Staccato™ Alprazolam for the treatment of Panic attacks associated with panic disorder. This study will provide an initial assessment of efficacy, and to continue to describe the tolerability and pharmacokinetics, of a single inhaled dose of Staccato Alprazolam on a doxapram-induce...
What is the current status of trial NCT00477451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2007-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00477451?
The interventions under investigation include: Inhaled placebo (DRUG), Inhaled alprazolam 1 mg (DRUG), Inhaled alprazolam 2 mg (DRUG), IV doxapram (DRUG).
Who is sponsoring clinical trial NCT00477451?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.